Back to today’s briefing

Story perspectives

Study Links DNMT3A Mutation to Increased Blood Cancer Risk

5/4/2025

31 2

Summary

Story summary

A groundbreaking study from Australia’s Olivia Newton-John Cancer Research Institute and WEHI reveals that a mutation in the DNMT3A gene undermines tumor-suppressing pathways, heightening the risk of blood cancers. By disrupting p53 signaling, this mutation enables cancerous stem cells to flourish. Targeting p53 could pave the way for more effective treatments for acute myeloid leukemia.

1 of 1

Story summary

A groundbreaking study from Australia’s Olivia Newton-John Cancer Research Institute and WEHI reveals that a mutation in the DNMT3A gene undermines tumor-suppressing pathways, heightening the risk of blood cancers. By disrupting p53 signaling, this mutation enables cancerous stem cells to flourish. Targeting p53 could pave the way for more effective treatments for acute myeloid leukemia.